Precision Medicine Approach to Targeting Neurodegeneration

A method of screening a subject for exclusion from a clinical trial for a neuroprotection agent, the method comprising:

• obtaining a blood, plasma or serum sample from the subject comprising both biochemical and protein biomarkers;
• determining if the subject is of Mexican American or of non-Hispanic white origin;
• measuring in the blood, plasma or serum sample a level of one or more biochemical biomarkers selected from the group consisting of:
• cholesterol, triglycerides, HDL cholesterol, glucose, HBAc1, LDL cholesterol, and glucagon;
• or
• measuring in the blood, plasma or serum sample an expression level of one or more protein biomarkers selected from the group consisting of:
• alpha-2-microglobulin (A2M), Factor VII, tenacin C (TNC), IL-18, Ab42, neurofilament light (NfL), Aβ40, Chemokine (C-C Motif) Ligand 17 (TARC), IL-6, tumor necrosis factor alpha (TNFα), beta-2-microglobulin (B2M), IL-5, thrombopoietin (TPO), I309, serum amyloid A1 cluster (SAA), insulin, pancreatic polypeptide (PPY), peptide YY (PYY), tau, GLP-1, fatty acid binding protein 3 (FABP3), soluble intracellular adhesion molecule (sICAM-1), soluble vascular adhesion molecule (sVCAM-1), eotaxin-3, IL-7, C-reactive protein (CRP), and IL-10, or both biochemical and protein biomarkers;
• comparing the level of expression from the sample with a statistical sample representative of a subject of Mexican American or of non-Hispanic white origin, suspected of having neurodegeneration;
• and
• determining that the subject has a neurodegeneration profile based on the expression level of the one or more biomarkers;
• and
• excluding the subject for inclusion in the clinical trial targeting neuroprotection if the subject has the neurodegeneration profile.